Welcome to our dedicated page for Igm Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGM Biosciences, Inc. (IGMS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents filed with the U.S. Securities and Exchange Commission. As a former Nasdaq-listed issuer, IGM Biosciences filed annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its clinical-stage biotechnology activities, financial position, collaboration revenues, operating expenses and risk factors related to its engineered IgM antibody platform.
Among the notable filings is a Form 8‑K dated July 1, 2025, in which IGM Biosciences reports entering into an Agreement and Plan of Merger with Concentra Biosciences, LLC and a merger subsidiary. This filing outlines the structure of the cash tender offer and subsequent merger, the treatment of common stock, stock options, restricted stock units and certain pre‑funded warrants, and the creation of contingent value rights tied to closing net cash and potential future dispositions of specified product candidates and intellectual property.
Investors researching IGMS can also review a Form 25 filed with the SEC, which notifies the removal of IGM Biosciences’ common stock from listing and registration on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. A later Form 15 filing certifies the termination of registration of the company’s common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), indicating that IGM Biosciences has deregistered its common stock and ceased ongoing Exchange Act reporting for that class of securities.
Stock Titan’s interface surfaces these filings in chronological order and can pair them with AI-powered summaries to highlight key points, such as changes in listing status, merger terms, cash thresholds, contingent value right mechanics and other material provisions. Users can quickly locate Forms 10‑K and 10‑Q for detailed historical financial and pipeline information, Forms 8‑K for material events, and the Form 25 and Form 15 that document the company’s transition from a publicly listed, reporting issuer to a wholly owned subsidiary following the Concentra transaction.
IGM Biosciences completed a merger in which all outstanding common and non-voting shares were cancelled and converted into cash and contingent value rights. Under the merger agreement, each share of common and non-voting stock was converted into $1.247 in cash plus one contractual contingent value right (CVR) governed by a separate CVR agreement. Reporting person Christina Teng Topsoe reported disposals tied to the transaction: 54,235 shares disposed directly and 10,410,364 shares disposed indirectly (comprised of 10,400,564 and 9,800 shares held through affiliated entities), and 5,044,295 non-voting shares (underlying common shares) were disposed in the derivative table; following the transactions the reported beneficial ownership is zero. The filing states pre-merger shareholdings were held through Topsoe Holding A/S and Pillarcater LLC with related disclosure of shared voting or pecuniary interests.
IGM Biosciences director Elizabeth H.Z. Thompson reported a disposition of 7,196 shares of the company’s common stock on 08/14/2025 in connection with the completion of a merger. Under the Merger, each outstanding share of IGM common stock was cancelled and converted into the right to receive $1.247 in cash plus one contractual contingent value right (CVR) governed by a Contingent Value Rights Agreement. Following the reported transaction the reporting person beneficially owned 0 shares of common stock.
The filing is a Form 4 disclosure of insider changes tied directly to the Merger transaction and shows the insider’s equity position was eliminated as part of the deal consideration.
IGM Biosciences insider Form 4: Director William Strohl reported a disposition of 125,000 shares of IGM Biosciences common stock on 08/14/2025, leaving him with 0 shares following the transaction. The filing explains this disposal resulted from a merger in which Concentra Merger Sub V, Inc. merged into IGM Biosciences and the company became a wholly owned subsidiary of Concentra Biosciences, LLC. Each outstanding share of common stock was cancelled and converted into the right to receive $1.247 in cash and one contingent value right (CVR) under a Contingent Value Rights Agreement.
IGM Biosciences insider report: Mary Beth Harler, who serves as both Chief Executive Officer and a director, reported the disposition of 323,680 shares of IGM Biosciences common stock on 08/14/2025. Following the reported transaction, Harler beneficially owned 0 shares. The filing explains these shares (including previously reported restricted stock units) were cancelled and converted as part of a merger transaction: each outstanding share and RSU was converted into $1.247 in cash plus one contractual contingent value right under a Contingent Value Rights Agreement. The Form 4 indicates the change in beneficial ownership resulted from the merger consummated on that date.
IGM Biosciences completed a merger on August 14, 2025 that converted all outstanding common stock into cash and contingent value rights. Under the Agreement and Plan of Merger, Merger Sub merged into IGM with IGM surviving as a wholly owned subsidiary of Concentra Biosciences, LLC (Parent). Each share of IGM common stock was cancelled and converted into $1.247 in cash plus one contractual contingent value right (CVR) governed by a Contingent Value Rights Agreement. Reporting person M. Kathleen Behrens, a director, reported dispositions of all her previously held shares, including shares held directly and indirectly through trusts, resulting in zero common shares beneficially owned following these transactions.
IGM Biosciences completed a merger and terminated its S-8 offerings, removing unsold registered securities. Under an Agreement and Plan of Merger dated July 1, 2025, IGM merged into a Concentra Biosciences subsidiary and became a wholly owned subsidiary of Concentra when the merger closed on August 14, 2025. Each outstanding share of IGM common stock (other than treasury shares, shares held by Parent/Merger Sub, and shares of stockholders who properly exercised appraisal rights) was converted into $1.247 in cash per share and one non-transferable contractual contingent value right (CVR) per share. As a result of the Merger, the registrant terminated all offerings under the listed Form S-8 registration statements and filed post-effective amendments to withdraw and remove any unissued and unsold securities that remained registered.
IGM Biosciences completed a merger into a subsidiary of Concentra Biosciences and, as a result, has terminated and withdrawn unissued securities from multiple Form S-8 registration statements. The Registrant entered into a merger agreement on July 1, 2025, and on August 14, 2025 Merger Sub was merged into the company with the company surviving as a wholly owned subsidiary of Parent.
Under the Merger each outstanding share (other than treasury shares, shares owned by Parent/Merger Sub, and shares of stockholders who validly exercised appraisal rights) was converted into the right to receive $1.247 in cash per share plus one non-transferable contractual contingent value right per share. The company removed all unsold securities registered under the referenced S-8 registration statements and terminated their effectiveness.
The registrant, IGM Biosciences, Inc., has filed post-effective amendments to multiple Form S-8 registration statements to withdraw and remove any unissued and unsold securities that remained registered under those statements after the termination of the offerings. The withdrawals follow the closing of a merger in which Concentra Merger Sub V, Inc. merged into IGM with IGM surviving as a wholly owned subsidiary of Concentra Biosciences, LLC. Under the merger each outstanding share (with customary exceptions) was converted into $1.247 in cash per share plus one non-transferable contingent value right per share. As a result, the company terminated all offerings made under the listed registration statements and has removed the unsold registered shares from registration.
IGM Biosciences completed a merger into Concentra Biosciences and terminated its pending employee equity registrations. Under a Merger Agreement dated July 1, 2025, the company was merged into a Concentra subsidiary on August 14, 2025, and became a wholly owned subsidiary of Concentra. Each outstanding public share (with limited exceptions) was converted into $1.247 in cash per share plus one non-transferable contingent value right per share. As a result, the registrant has ended all offerings under multiple Form S-8 registration statements and filed post-effective amendments to withdraw any unissued and unsold securities that remained registered.
IGM Biosciences, Inc. filed post-effective amendments to multiple Form S-8 registration statements to withdraw and remove any unissued and unsold securities after the company completed a merger. The company entered into a Merger Agreement on July 1, 2025, and on August 14, 2025 the merger closed with Concentra Merger Sub V, Inc. merging into IGM and IGM surviving as a wholly owned subsidiary of Concentra Biosciences, LLC. As part of the merger, each outstanding share of IGM common stock (subject to limited exceptions) was converted into $1.247 in cash per share and one non-transferable contractual contingent value right (CVR) per share. Because the company is now a wholly owned subsidiary, it has terminated all offerings of its securities under the listed registration statements and removed from registration all unsold securities covered by those statements.